Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Company Strategy - The company is in discussions with multiple potential animal health partners to expand the indication and commercialize Canalevia for the treatment of general diarrhea globally [1] - Canalevia, known as Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs [1] Financial Support - The company has received notice of a $250,000 grant from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) [1]